What do systematic reviews say?

MSCs vs placebo or control

The review found no eligible studies for this question.

• Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Combined interventions vs usual care

• Interventions to support return to work for people with coronary heart disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  Low

Effects of school‐based asthma interventions vs usual care

• School‐based self‐management interventions for asthma in children and adolescents: a mixed methods systematic review 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 2587 participants
  Moderate

Fluoxetine vs placebo

The review found no eligible studies for this question.

• Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

mTOR inhibitors vs chemotherapy/hormone therapy

The review found no eligible studies for this question.

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

TACE followed by 3‐DCRT vs chemoembolisation

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 66 participants
  Very low

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

The review found no eligible studies for this question.

• Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

The review found no eligible studies for this question.

• Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs control (e.g. usual activities)

• Exercise for preventing falls in older people living in the community 2019 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 3172 participants
  Low

Less intensive vs more intensive follow‐up after primary cancer treatment

• Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2742 participants
  Very low

Intraoperative neuromonitoring vs visual nerve identification only during thyroidectomy

The review found no eligible studies for this question.

• Intraoperative neuromonitoring versus visual nerve identification for prevention of recurrent laryngeal nerve injury… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐alpha reductase inhibitors vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐inflammatories vs control

The review found no eligible studies for this question.

• Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found